Boston Scientific to acquire BTG

Boston Scientific has set aside $4 billion to acquire BTG, a company with three key businesses – the interventional medicine portfolio which includes several peripheral interventional product lines, the interventional oncology franchise which includes the TheraSphere Y-90 radiotherapy microspheres, and the GALIL cryoablation system, used to treat patients with liver, kidney and other cancers. The BTG portfolio also includes their vascular portfolio of filters, crossing catheters, microfoam and the EKOS Endovascular System, acute care antidotes to treat overexposure to certain medications and toxins, and a licensing business that receives royalties relating to products subject to BTG intellectual property and license agreements.
Chairman and CEO of Boston Scientific, Mike Mahoney, said: “The acquisition of BTG and its rapidly growing peripheral interventional portfolio is an exciting extension of our category leadership strategy that will augment our capabilities in important areas of unmet need such as cancer and pulmonary embolism. We are confident that the addition of these therapies to our portfolio will ultimately advance patient care in ways that could not be realized by either company alone, while also allowing us to realize substantial revenue and cost synergies and provide a strong return for investors.”